Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform.
The laboratories of Dr. Kevin Bender and Dr. Nadav Ahituv at the University of California, San Francisco, today announced the publication of preclinical proof-of-concept data demonstrating that CRISPR activation restores SCN2A expression and ameliorates disease-related phenotypes in mouse and human models of SCN2A-haploinsufficiency.
Regel Therapeutics Appoints Stephen J. Farr as New Chief Executive Officer
CAMBRIDGE, Mass. and BERKELEY, Calif., PRNewswire -- The Board of Directors of Regel Therapeutics, a gene regulation company, announced that Stephen J. Farr, PhD, begins today as Chief Executive Officer (CEO).
Regel Therapeutics Awarded $1 Million from HS Chau Women in Enterprising Science Program at the Innovative Genomics Institute to Continue Developing its Gene Modulation Technology.
CAMBRIDGE, Mass. and BERKELEY, Calif. /PRNewswire/ -- Regel Therapeutics, today announced that it will receive $1 Million in non-dilutive funding from the HS Chau Foundation through the Women in Enterprising Science Program (WIES) at the Innovative Genomics Institute (IGI).
Regel Therapeutics announces its participation at the Dravet Syndrome Conference and attendance at the European Dravet Syndrome Advanced Therapies Meeting in Madrid, Spain on March 23rd and 24th 2023.
CAMBRIDGE, Mass., and BERKELEY, Calif. / PRNewswire -- Regel Therapeutics, today announced that Jordane Dimidschstein, Ph.D., co-founder and COO, will present Regel’s technology and pipeline at the Dravet Conference Meeting 2023 in Madrid on March 23.
Regel Therapeutics launches its website and welcomes Andrew Schiermeier to its Board of Directors.
CAMBRIDGE, Mass., and BERKELEY, Calif. / PRNewswire -- Regel Therapeutics, today announce the launch of its website, the addition of Andrew Schiermeier, Ph.D to its Board of Directors and the establishment of its Scientific Advisory Board.
